Single-dose cefixime versus single-dose ceftriaxone in the treatment of antimicrobial-resistant Neisseria gonorrhoeae infection

J Infect Dis. 1992 Oct;166(4):919-22. doi: 10.1093/infdis/166.4.919.

Abstract

Sexually transmitted diseases (STDs) have a significant adverse effect on reproductive and child health worldwide. The control of STDs such as gonorrhea is therefore an absolute priority. Cefixime, an oral third-generation cephalosporin with in vitro activity similar to that of ceftriaxone, may be an effective candidate for the treatment of gonorrhea. The efficacy of a single oral 400-mg dose of cefixime was compared with that of a single intramuscular 250-mg dose of ceftriaxone for the treatment of Neisseria gonorrhoeae urethritis in 190 men and cervicitis in 46 women in Nairobi, Kenya. A bacteriologic cure was recorded in 100% of 63 evaluatable patients treated with ceftriaxone and 118 (98%) of 121 evaluatable patients treated with cefixime. Cefixime, as a single oral dose, is an effective alternative for the treatment of uncomplicated gonococcal urethritis in men and cervicitis in women.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Anti-Bacterial Agents / administration & dosage*
  • Cefixime
  • Cefotaxime / administration & dosage
  • Cefotaxime / analogs & derivatives*
  • Cefotaxime / therapeutic use
  • Ceftriaxone / administration & dosage*
  • Ceftriaxone / therapeutic use
  • Drug Evaluation
  • Female
  • Gonorrhea / drug therapy*
  • Humans
  • Injections, Intramuscular
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Neisseria gonorrhoeae / drug effects*
  • Urethritis / drug therapy*
  • Urethritis / microbiology
  • Uterine Cervicitis / drug therapy*
  • Uterine Cervicitis / microbiology

Substances

  • Anti-Bacterial Agents
  • Ceftriaxone
  • Cefixime
  • Cefotaxime